Adempas (riociguat)

**Override(s)** | **Approval Duration**
---|---
Prior Authorization | 1 year
Quantity Limit

**Medications** | **Quantity Limit**
---|---
Adempas (riociguat) 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg | May be subject to quantity limit

**APPROVAL CRITERIA**

Requests for Adempas (riociguat) may be approved if the following criteria are met:

I. Individual has a catheterization-proven diagnosis\(^2\) of pulmonary arterial hypertension (PAH) [World Health Organization (WHO) Group 1]\(^3\); **AND**

II. Individual has WHO functional class II-IV\(^4\) symptoms;

**OR**

III. Individual has a catheterization-proven diagnosis\(^2\) of chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4); **AND**

IV. Individual is using for one of the following:
   A. Persistent or recurrent pulmonary hypertension after at least 180 days following surgical treatment with pulmonary endarterectomy; **OR**
   B. Inoperable (via pulmonary endarterectomy) CTEPH;

**AND**

V. Individual has WHO functional class II-IV\(^4\) symptoms.

Adempas (riociguat) may **not** be approved for the following:

I. Individual has a diagnosis of severe hepatic impairment (Child-Pugh Class C); **OR**

II. Individual is on dialysis or has a creatinine clearance less than 15 mL/min; **OR**

III. Individual has a diagnosis of pulmonary veno-occlusive disease (PVOD); **OR**

IV. Individual has a diagnosis of pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP); **OR**

---

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

WEB-PEC-0590-17
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
D. Class IV: Inability to carry out any physical activity without symptoms. Dyspnea and/or fatigue may be present at rest and discomfort is increased by any physical activity.

### State Specific Mandates

<table>
<thead>
<tr>
<th>State name</th>
<th>Date effective</th>
<th>Mandate details (including specific bill if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Key References:**


DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.